GMEDHIGH SIGNALFINANCIAL10-K

GMED delivered exceptional financial performance with net income surging 422% to $538M, driven by successful integration of the NuVasive acquisition and strong operational execution.

The dramatic improvement in profitability metrics, combined with significantly reduced debt load and increased share buyback activity, indicates the company has successfully navigated the NuVasive integration challenges that were previously flagged as major risk factors. The removal of integration-related risk language from forward-looking statements suggests management believes the most challenging phase of the merger is behind them.

Comparing 2026-02-24 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

GMED's financials show a company firing on all cylinders, with net income exploding 422% and operating income nearly tripling, while gross profit grew a more modest 34%, indicating dramatic operational leverage and cost synergies from the NuVasive deal. The balance sheet strengthened considerably with total liabilities dropping 32% and current liabilities declining 42%, though cash decreased 33% likely due to aggressive share buybacks that increased 250% to $301M. Overall, the financial picture signals a successful post-acquisition integration with the company now generating substantial cash flows and aggressively returning capital to shareholders while maintaining growth investments through higher capex.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+422.3%
$103.0M$537.9M

Net income grew 422.3% — bottom-line growth signals improving overall business health.

Share Buybacks
Cash Flow
+250.2%
$85.8M$300.5M

Share repurchases increased 250.2% — management returning capital, signals confidence in intrinsic value.

Operating Income
P&L
+189.1%
$166.0M$479.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+44.7%
$520.6M$753.4M

Operating cash flow surged 44.7% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
+42.7%
$115.4M$164.7M

Capital expenditure jumped 42.7% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
-41.8%
$855.9M$498.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
+34.4%
$759.1M$1.0B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
-32.9%
$784.4M$526.2M

Cash declined 32.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-32.1%
$1.1B$729.5M

Liabilities reduced 32.1% — deleveraging improves balance sheet strength and financial flexibility.

Accounts Receivable
Balance Sheet
+21.7%
$557.7M$678.9M

Receivables grew 21.7% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-20
ADDED
(Exact name of registrant as specified in its charter) DE LAWARE 04-3744954 (State or other jurisdiction of incorporation or organization) (I.R.S.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48 I tem 6.
Except as may be required by law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
With 9 product launches in 2025 and operations across 65 countries worldwide, we offer a comprehensive portfolio of innovative and differentiated technologies that are used to treat a variety of musculoskeletal conditions.
NuVasive Merger As previously disclosed, on September 1, 2023, pursuant to that certain merger agreement (the NuVasive Merger Agreement ) with NuVasive, Inc.
+7 more — sign up free →
REMOVED
(Exact name of registrant as specified in its charter ) DELAWARE 04-3744954 (State or other jurisdiction of incorporation or organization) (I.R.S.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48 Item 7.
These risks and uncertainties include, but are not limited to, t he risks and costs associated with the integration of the NuVasive business and Globus Medical, Inc.
s ability to successfully integrate and achieve anticipated synergies with the NuVasive business , our ability to complete the acquisition of and successfully integrate the Nevro, Inc.
We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →